EG BioMed was honored with two major accolades in the SME category at the 23rd Golden Peak Awards: “Top 10 Outstanding Leaders” and “Top 10 in Innovation and R&D”. At the award ceremony held on April 25, 2025, Chairman Hsieh-Tsung Shen accepted the honors on behalf of the company, marking an important recognition from the industry.
The Golden Peak Awards are among Taiwan’s most prestigious business honors. Organized by the Chinese Professional Management Association, the awards are judged by a panel of experts from academia and industry, evaluating companies on business strategy, technological innovation, social impact, and future growth potential. These awards highlight excellence in highly competitive environments.
The “Top 10 Outstanding Leaders” award recognizes Chairman Shen’s strategic vision in leading the company’s continuous innovation and global advancement. It also affirms EG BioMed’s strength in forward-looking industry development and international competitiveness.
Chairman Hsieh-Tsung Shen of EG BioMed attended the 23rd Golden Peak Awards ceremony on April 25, 2025, and accepted the award on behalf of the company.
Specializing in cfDNA methylation detection, EG BioMed has developed a highly sensitive, non-invasive, and clinically applicable multi-cancer blood testing platform. These dual honors reflect the company’s achievements in advancing early cancer detection technologies and global regulatory presence—reinforcing our commitment to transforming innovation into real-world medical impact.
EG BioMed’s Multi-Cancer Blood Testing Platform integrates proprietary methylation probes with an automated qPCR workflow. Requiring only 8 mL of blood, the platform delivers analytical reports in as fast as two days—making it well-suited for clinical screening, post-treatment monitoring, and precision diagnostics.
Three major tests have been developed and clinically validated:
- EG-Pancreatic Blood Test-E1 (for pancreatic cancer)
- EG-Breast Blood Test-P1 (for breast cancer follow-up)
- EG-Colon Blood Test-E1 (for early-stage colorectal cancer)
EG BioMed has analyzed over 950 clinical samples across its three assays, each achieving an overall accuracy above 90%. Since launching its global patent strategy in 2019, the company has obtained patents in Taiwan, the EU (covering 19 countries), China, Malaysia, the U.S., Japan, Singapore, and Australia. In parallel with its R&D and regulatory efforts, EG BioMed has established a CLIA-certified laboratory in Washington State. CAP accreditation and participation in the FDA Breakthrough Devices Program are currently underway to support clinical implementation. The company continues to enhance its platform, expand to additional cancer types, and advance global clinical validation—reinforcing the practical value of precision medicine.
Being honored with dual awards at the Golden Peak Awards is not only a recognition of our team’s efforts, but also a strong motivation to keep innovating. EG BioMed will continue striving to contribute to Taiwan’s medical innovation.